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Summary 
Interleukin-10  (IL-10) is a recently described pteiotropic  cytokine secreted  mainly by type 2 
helper T  cells.  Previous studies have shown that IL-t0 suppresses cytokine expression by natu- 
ral killer (NK) and type 1 T  cells,  thus down-regulating cell-mediated immunity and stimulat- 
ing humoral responses.  We here report that injected  IL-t0 protein  is an efficient inhibitor of 
tumor  metastasis  in  experimental  (B16-F10)  and  spontaneous  (M27  and  Lox human  mela- 
noma)  metastasis  models in vivo at doses that do not have toxic effects on normal or cancer 
cells.  Histological  characterization  after IL-10 treatment  confirmed the absence of CD8 + and 
CD4 + T  cells  and macrophages at the sites  of tumor growth, but abundant NK  cells were lo- 
calized at these  sites.  This  unexpected  finding was confirmed by showing that IL-10 inhibits 
most B16-F10 and Lox metastases in mice deficient in T  or B  cells  (SCID and nu/nu  mice), 
but not in those deficient in NK cells  (beige mice or NK cell--depleted mice). However, IL-t0 
downregulation of pro-inflammatory cytokine production and/or recruitment of additional ef- 
f~ctor cells may also be involved in the anti-tumor effect at higher local concentrations of IL-t0, 
since transfected B16 tumor cells  expressing high amounts of lL-10 were rejected by normal, 
nu/nu, or SCID mice at the primary tumor stage, and there was still a 33% inhibition of  tumor 
metastasis in beige mice. 
A 
number  of cytokines  have  been  used  with  variable 
success in attempts to control tumor growth and me- 
tastasis  (1-8). Many of these cytokines, such as IL-2, IFN~/, 
TNFo~, and GM-CSF, also have direct toxic or stimulatory 
effects  on the  tumor cells,  and may in  some cases lead  to 
malignancy of otherwise  normal  cells  (4,  9),  thus  compli- 
cating their clinical usefulness. We have therefore screened 
a number ofcytokines for their ability to inhibit tumor me- 
tastases,  and found that one of them,  IL-10, is an efficient 
inhibitor  of tumor metastasis  in vivo at  doses  that  do not 
have a direct effect on normal or cancer cells.  IL-10 acts on 
different  cell  types,  stimulating  differentiation  of B  cells 
into antibody-secreting cells,  and inhibiting the capacity of 
monocytes/macrophages  to  present  antigens  (10-12).  In 
addition,  IL-10  exerts  an  indirect  effect  on  the  immune 
system, by inhibiting the secretion of proinflammatory cy- 
tokines (IL-1, IL-6, IL-8, GM-CSF, and TNFc~) from type 
1  helper  T  cells,  monocytes/macrophages,  and  polymor- 
phonuclear  Ieukocytes, and  by inhibiting  the  secretion  of 
IFN~/by NK cells  (12-15). Recent studies have shown that 
IL-IO  downregulates  cell-mediated  responses  and  favors 
the humoral arm of immunity by decreasing production of 
cytokines  involved  in  cell-mediated  responses  (12),  and 
that IL-10 increases the susceptibility to bacterial and para- 
sitic infections (16,  17). We therefore also investigated the 
mechanism by which IL-10 inhibits  tumor metastasis.  We 
find  that  NK cells  are  the  main  effector cells  recruited  at 
the  nontoxic concentrations  of IL-10 used here,  although 
other  effector  cells  and/or  mechanisms  may  also  be  in- 
volved at higher IL-10 concentrations. 
Materials and Methods 
Tumor Cells and Experimental Animals.  For  all  the  experi- 
ments described here, 6--8-wk-old female C57/BL6 and BALB/C 
mice  were  purchased  from  Charles  River  Labs. (Wilmington, 
MA).  The B16-F10 murine  melanoma was provided by Dr.  I. 
Fidler and M27 murine lung carcinoma by Dr. P. Brodt. Human 
IL-10 (hlL-10) was obtained from Schering-Plough Corp. (Union, 
NJ),  and its specific activity was 3.1  ￿  107 U/rag. Athymic nu/ 
nu mice, beige mice, and SCID mice were from Harlen Spraque 
Dawley. 
Tumor Measurements.  Experimental lung metastases were ob- 
tained after intravenous injection of B16-F10 murine melanoma 
cells in C57/BL6  (H-2  b) mice,  athymic nu/nu mice, and beige 
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ous injection of M27  Lewis  lung carcinoma cells in C57/BL6 
mice, and Lox human melanoma cells in SCID mice. hlL-10 (up 
to  150  ~g/kg)  was injected intraperitoneaUy.  Tumor diameters 
were measured with calipers,  groups  of 10 mice were used for 
each condition, and each experiment was repeated  at least twice. 
The number of lung metastases was determined in double-blind 
measurements.  Statistical analysis was performed using the non- 
parametric  one tailed Mann-Whitney U test. 
For experiments with mice depleted of NK ceils, mice were 
injected intravenously with  100  I~g  of a  mAb  against  NKI.1 
(PharMingen, San Diego, CA) on day -1, day 0 and day 1 after 
injection of tumor cells (1  ￿  105 ceils/animal).  Animals received 
IgG2a isotype  antibodies as  a control for  the  specificity  of the 
anti-NKl.1 mAb. Treatment with hlL-10 started on day 0, day 1 
and  day  2  after  tumor  cell  injection.  Lung  metastases  were 
counted on day 14. 
For experiments with tumor ceils transfected  with the  IL-10 
gene, cells were co-transfected  with pSV2 neo and a plasmid con- 
taining the human IL-10 gene. G418-resistant colonies were iso- 
lated, and IL-10 protein secretion was measured by ELISA. 
Immunohistological Analysis.  Sections for immunohistochemis- 
try were prepared  and labeled with antibodies as previously de- 
scribed (18). Monoclonal antibodies against CD3 (500 A2), CD4 
(L3T4),  CD8  (Lyt2), CD90 (Thy-1), NK-I.1, and Mac-3 were 
from PharMingen; against LGL-I  (4Dll), from Dr.  L.  Mason; 
against asialo-GM~, from Wako Chemicals US (Richmond, VA); 
against  Mac-1  and Mac-2,  from Boehringer Mannheim Corp. 
(Indianapolis,  IN); and mAb BMA-BM8 against resident tissue 
macrophages, from Accurate Chemical & Scientific Corp. (West- 
bury, NY) 
Results 
Direct Effect of lL-IO on  Tumor Cells In  Vitro and In  Vivo. 
In preliminary experiments, it was established that hlL-10 
does not have direct toxic or stimulatory effects on the tu- 
mor cells when tumor cell lines are treated in vitro with up 
to  1  btg/ml (corresponding to  10  s  U/m/)  of hlL-10  (not 
shown). Likewise, no discernible toxic effect was observed 
in  mice  when  hlL-10  doses  as  high  as  700  txg/kg  were 
used, although primary tumor growth in animals was par- 
tially affected  by treatment with higher concentrations of 
hlL-10.  Thus,  murine  monocytic  (nu/nu  or  BALB/c 
mice)  and OVCAR  5  human ovarian (nu/nu mice)  pri- 
mary tumors were not affected by hlL-10 doses from 5 to 
250  l*g/kg daily, while higher doses inhibited slightly the 
growth  of B16-F10  murine melanoma  (nu/nu or  C57/ 
BL6)  and U937  (nu/nu)  tumors  (<~40%  inhibition) (not 
shown). 
Effect of lL- I0 on Tumor Metastasis.  In  order  to  measure 
the effects  of IL-10 on tumor metastasis in animals, hlL-10 
(up to  150 I~g/kg) was injected intraperitoneally following 
various doses and schedules. Daily injection of hlL-10 re- 
duced significantly the number of lung metastases in both 
spontaneous and experimental models. The inhibition was 
dose-dependent, as  shown in Fig.  1  for  the  experimental 
metastatic model (B16 cells) and the spontaneous metastatic 
model  (M27  cells).  Inhibition in C57/BL6  mice reached 
68.4% for B16-F10 tumors at  150  Ixg/kg,  and 90.2%  for 
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Figure 1.  Inhibitory effect of hlL-10 on lung metastasis in C57/BL6 
mice of (A) B16 and (B) M27 tumors. Mice were injected intravenously 
with 1 ￿  10  s B16 or subcutaneously  with 2 ￿  l0  s M27 cells on day 0, 
and hlL-10 treatment was initiated on day 1. Mice treated with hlL-10 
exhibited a 64.3% (P = 0.008) inhibition  of metastasis at a dose of 10 p.g/kg 
IL-10, 58.8% (P = 0.01) at a dose of 100 I~g/kg, and 68.4% (P = 0.002) 
at a dose of I50 txg/kg for B16 tumors on day 9 after injection; and mice 
treated with 100 b~g/kg and 150 ~g/kg ofhlL-10 exhibited  a 90.2% (P = 
0.003) and 80.4% (P =  0.048) inhibition of metastasis, respectively, for 
M27 tumors on day 28, compared with the vehicle control groups (Veh). 
M27 tumors. Moreover, treatment does not need to begin 
at the same time as tumor implantation, since administra- 
tion ofhlL-10 for 3  d  starting on the day after tumor cell 
inoculation results in a  66.1%  inhibition of metastases  of 
B 16 tumors (not shown). 
It has recently been shown that Chinese hamster ovary 
(19)  or  mammary  adenocarcinoma cells  transfected  (20) 
with the IL-10 gene were less effective at establishing pri- 
mary  tumors  than  untransfected  cells.  We  therefore  in- 
jected animals with B16-F10 tumor cells transfected with 
the gene coding for hlL-10 and secreting different amounts 
of hlL-10  to  ascertain whether  they  displayed metastatic 
behavior. Some of the transfected tumor cells were not able 
to form solid tumors, and metastases were  also effectively 
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Figure 2.  Effects  ofIL-10-gene transfected B16 tumors. (A) Inhibition 
of solid tumor growth (tumor size given as a function of time, in days). 
C57/BL6 mice were injected subcutaneously with 1 ￿  106 IL-10-trans- 
fected B16 clones secreting varying amounts of IL-10. Compared to the 
B16 cell line transfected with the plasmid control (B16-Vector), there was 
100% inhibition of primary tumor growth for B16 clone #IA, and over 
50% inhibition for clones #4 and #9. Groups of ten mice were used for 
each clone, and each experiment was repeated at least twice. (/3) Inhibi- 
tion orB16 metastases. Mice were injected intravenously with 1 ￿  l0  s 
B16 cells transfected with the IL-10  gene. Mice were killed on day 9, and 
the lung metastases were counted. Lung metastasis inhibition for each 
clone was as follows: #1A, 100%; #4, 86.4%; #5, 89.6%; #8, 94.7%; #9, 
85.8%; #17,  92%. IL-10 secretion (in ng/million  cells/48 h) for each 
clone was as follows: clone #1A, 400-500; #4, 11.8; #5, 3.5; #8, 6.3; #9, 
5.9; #17, 1.4. 
day 28 after subcutaneous injection of 2  ￿  105 transfected 
cells was 82 and 84.3%, respectively (not shown). 
Identification  of Effector Cells  Involved  in Metastasis  Inhibi- 
lion.  Previous studies  have demonstrated that macrophages 
(2, 3, 21), helper T  cells (22, 23), cytotoxic T  ceils (1, 7, 8), 
and NK cells (7, 24) may contribute to the rejection of tu- 
mors  treated  with  different  cytokines  or transfected  with 
genes coding for those cytokines. In order to determine the 
nature  of the effector cells responsible  for IL-10-mediated 
inhibition  of tumor metastases,  the phenotype of immune 
cells  invading the  tissues  was  studied  by immunostaining. 
Cells  expressing  markers  of helper  (CD4+),  cytotoxic  T 
(CD8 +)  lymphocytes, or macrophages  (Mac-1 +, Mac-2 +, 
Mac-3 +,  and  the  macrophage  epitope  BMA  BM8)  were 
rarely  if ever observed  (not shown).  Few  cells  expressing 
NK cell markers were found in normal tissues (not shown) 
or tumors of untreated mice (Fig.  3 A), but abundant NK 
cells  were  localized in B16  subcutaneous  tumors  of mice 
treated with hlL-10 (Fig. 3  B) and in subcutaneous tumors 
of mice  injected  with  IL-10  gene--transfected  B16  ceils 
(Fig.  3  C).  When double immunostaining was performed 
on  the  cells  expressing  the  NK  cell  asialo-GMl  antigen 
(Fig.  3  D),  these  were  found  to  also  express  the  LGL-1 
marker  typical  of  activated  large  granular  lymphocytes 
(Fig. 3 E). 
Metastasis Inhibition in Various Mouse Models.  The involve- 
ment of NK cells was confirmed by comparing inhibition 
of tumor  metastases  in  normal  C57/BL6  mice,  athymic 
ma/nu  mice,  SCID  mice,  beige  mice,  and  mice  that  had 
been depleted of NK cells  (Table  1). While hlL-10 inhib- 
ited  most metastases  in  nu/nu  and  SCID  mice  (65.6  and 
64.3%  inhibition,  respectively),  there  was  little  inhibition 
in beige mice or NK cell-depleted mice (14 and  19%, re- 
spectively).  These  effects  were  paralleled  in  experiments 
with IL-10 gene-transfected cells.  There was complete me- 
tastasis  inhibition  in  nu/nu  and  SCID  mice  when  trans- 
fected  B16-F10  cells  were  inoculated  into  the  animals, 
whereas  there  was  only  33%  inhibition  when  the  trans- 
fected  cells  were  introduced  into  beige  mice.  Thus,  with 
both  treatments,  inhibition  was  much lower in  NK  cell- 
deficient  mice  (beige  mice  and  NK  cell-depleted  mice) 
than in SCID or nu/nu mice. 
inhibited.  Fig. 2 A  shows the growth in C57/BL6 mice of 
B16 tumor cells  transfected with the hlL-10 gene.  No de- 
tectable tumor growth was observed with a clone secreting 
400-500  ng IL-10/48 h/1  million  transfected  cells,  while 
significant growth inhibition  was also measured for clones 
expressing lower IL-10 levels (1.4 to 11.8 ng/million cells/ 
48 h).  Similarly, hlL-10 secretion by these transfected cells 
inhibited  metastasis  of all  the  B16  clones,  with  inhibition 
ranging from 85.8  to  100%  (Fig.  2  B).  Inhibition  of me- 
tastasis was also observed with two hlL-10 gene-transfected 
M27 clones, #G1  (secreting 50 ng/million cells/48 h)  and 
#G3  (28  ng/million  cells/48  h),  for which  inhibition  on 
Discussion 
We  used  a  number  of murine  and  human  tumor  cell 
lines to study the effects of recombinant human IL-10 (hiL- 
l0)  protein  and  of tumor  cells  transfected  with  the  IL-10 
gene  on  tumor  metastasis.  Experimental  lung  metastases 
were obtained after intravenous injection ofB16-F10 mu- 
rine melanoma cells  in normal mice, athymic nu/nu mace, 
beige  mice,  and  mice  depleted  of NK  cells  by  antibody 
treatment;  and spontaneous lung metastases were obtained 
by subcutaneous  injection  of M27  Lewis  lung  carcinoma 
cells in C57/BL6 mice, and Lox human melanoma cells  in 
SCID mice. We found that soluble IL-10 is able to inhibit 
metastasis  of  both  experimental  and  spontaneous  lung 
models at IL-10 concentrations that do not have direct in- 
581  Zheng et al. Figure 3.  Immunostaining  of tumors in C57/BL6 mice on day 18 after tumor cell injection.  LGL-1-FITC labeling of subcutaneous  tumors in (A) in 
untreated  control mice and (B) mice treated with 100 Izg/kg hlL-10 daily, starting on day 1. (C) Asialo-GM1-FITC labeling of subcutaneous  tmnors of 
IL  10 gene--transfected B16  cells. (D)  Double immunostaining  with asialo-GMt-FITC and  (E)  LGL-1-Rbodamine of subcutaneous  tumors  in  luice 
treated with 100 Ixg/kg hlL-10, on day 18. 
Table  1.  Inhibition q/Lung Metastases in Various Mouse Models 
Mouse model  Tumor 
% Inhibition:  % Inhibition 
100 b~g/kg  hlL-10 gene 
hlL-10  transfection 
nu/nu  B16-F10  65.6 %*  100% 
(P =  0.0019) 
scid  LOX  80.5%r  ND 
(P =  0.002) 
scld  B 16-F 10  64.3%*  100% 
(P--  0.004) 
beige  B16-FI0  14%*  33% 
NK cell-depleted  B16-F10  19%~  ND 
Tumor cells were transfected  with the hlL-10 gene as described  in the 
legend to Fig. 2, and B16-F10 clone #1A was used for the studies on 
inhibition with IL-10-gene transfected  cells. 
*Mice were inoculated with 5  ￿  10  4 cells/animal.  Treatment was be- 
gun on day 0.  The mean number of lung metastases was  counted  on 
day 9. 
*Mice were inoculated subcutaneously  with 5 ￿  105 cells into the flank 
on  day  0.  Treatment was  carried  out on day  1 through  day  22.  The 
mean number of lung metastases was counted on day 22. 
~Mice  were  depleted  of NK  cells with  an  anti-NKl.l  mAb,  as  de- 
scribed  m Materials  and  Methods.  In isotype  control experiments with 
lgG2a antibodies,  the same treatment with hlL-10 resulted  in a 64% in- 
hibition of tumor metastasis. 
hibitory  or stimulatory  effects on  the  tumors  in vitro or in 
vivo. 
Immunohistological  characterization  led  to  the  identifi- 
cation  of mostly NK  cells at the metastasis  sites.  These  his- 
tological observations  were  confirmed  by  tumor  metastasis 
measurements  in  different  mouse  models,  which  showed 
that there is good metastasis inhibition due to IL-10 in nor- 
mal mice, athymic nu/nu  mice (lacking T  cells), and SCID 
mice  (deficient  in  both  B  and  T  cells),  but  not  in  beige 
mice  (displaying  a  functional  deficiency  of NK  cells  and 
macrophages)  or  mice  specifically  depleted  of  NK  cells. 
Thus,  while  macrophages,  CD4 +  and  CD8 +  T  cells,  and 
NK  cells  have  been  observed  in  previous  studies  to  have 
antitumoral  effects in different situations,  the preponderant 
role of NK  cells in  eliminating metastases  m  IL-10-treated 
mice  is consistent  with  findings  that  IL-10  reduces  CD4 + 
antigen-specific  proliferation  by  downregulating  MHC 
class  II  expression  (10),  and  that  it  inhibits  macrophage 
activation,  cytokine and  nitrogen  oxide production,  expres- 
sion of B7,  mycobacteriostatic  activity, and tumor cytotox- 
icity  (12-!4,  25-28).  Likewise,  in  primary  mixed  lym- 
phocyte cultures,  IL-10 inhibits allogeneic proliferative and 
cytotoxic  responses  of CD4 +  and  CD8 +  T  cells  (29),  and 
preincubation  with IL-10 before exposure  to tumor-associ- 
ated  antigens  significantly  inhibits  delayed-type  hyper- 
sensitivity responses  (30).  In contrast,  1L-10 in combination 
with IL-2 increases IL-2-induced NK cell proliferation, and 
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tumor cells in vitro (31).  Furthermore,  consistent with our 
results on the inhibition of tumor metastasis in vivo, IL-10 
has been reported to render mouse lymphoma cells resistant 
to CTL and sensitive to NK-mediated tysis in vitro (32). 
Nonetheless, the observation that both 100 btg/kg hlL-10 
and cells  transfected with the hlL-10 gene caused measur- 
able  inhibition  in  beige  mice  (14  and  33%,  respectively) 
suggests  that,  although NK cells  may be  the  predominant 
effector mechanism  responsible  for inhibition,  IL-10 may 
also partially  inhibit  metastases  through other means,  such 
as  through  its  ability  to  downregulate  the  production  of 
pro-inflammatory  cytokines  and  chemokines  (12),  which 
enhance  the  expression  of tumor  cell  adhesion  molecules 
and  tumor  cell  migration  (33,  34).  In addition,  it  has  re- 
cently been reported that transfected adenocarcinoma cells 
secreting high quantities  of IL-10 (1,500--2,000 ng/million 
cells/48 h) are rejected by a combination of CD8 + T  lym- 
phocytes, NK cells  and neutrophils  (20), which would also 
be  consistent  with  our  observation  that  our  high  IL-10 
producing  B16-F10  clone  (secreting  400-500  ng/million 
cells/48 h) is rejected at the primary tumor stage in normal, 
nu/nu and SCID mice, and that there is still 33% inhibition 
of tumor metastasis in beige mice. 
The IL-10-mediated activation/recruitment  of NK cells 
observed in tumor metastases  is in  distinct  contrast to  the 
inhibition of NK cytokine production by monocytes/mac- 
rophages (15). While the mechanism used to activate and/ 
or recruit NK cells to sites  of metastasis in vivo remains to 
be elucidated,  it has recently been reported  that IL-10 in- 
hibits the synthesis of transforming growth factor (TGF)-[~ 
(35),  which  is  known  to  suppress  activation  of NK  cells 
(36, 37), and that NK cells express the IL-10 receptor (31). 
Given  the  many  pleiotropic  activities  of IL-10,  many  of 
which may indirectly affect NK cell function, it will be in- 
teresting to identify the multiple pathways by which IL-10 
may inhibit tumor metastasis. 
The  IL-10 protein appears  to have its  greatest  effect on 
tumor metastasis,  although we can not rule out at the mo- 
ment the possibility that the marginal effects on primary tu- 
mor growth may be  due  to an inability  of IL-10 injected 
intravenously to reach the tumor core, since one of our tu- 
mor  cell  clones  transfected  with  the  IL-10  gene  (clone 
#1A) failed to establish primary tumors. Work in our labo- 
ratories is in progress to determine if a synergism, acting on 
both primary and metastasizing tumors, may exist between 
IL-10 and  other cytokines,  such  as  IL-2 and  IL-4, which 
have  previously  been  reported  to  inhibit  primary  tumor 
growth  (1,  2,  7,  21).  Cancer  treatment  with  IL-10 to in- 
hibit metastases, combined with other cytokines or surgical 
intervention  to remove primary tumors,  may thus provide 
an effective means of thwarting the spread of many tumors. 
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